Do sodium glucose co-transporter-2 (sglt-2) inhibitors affect lower urinary tract, sleep and quality of life in people with type 2 diabetes?

Gökçen Güngör Semiz; Mehmet Emin Arayıcı; Ozan Bozkurt; Serkan Yener; Tevfik Demir

Makale detayları

Do sodium glucose co-transporter-2 (sglt-2) inhibitors affect lower urinary tract, sleep and quality of life in people with type 2 diabetes?

Yazarlar:

Gökçen Güngör Semiz | Mehmet Emin Arayıcı | Ozan Bozkurt | Serkan Yener | Tevfik Demir

Yayıncı:

Dokuz Eylul University

Ana Başlıklar:

Endocrinology

Dergi:

Journal of Basic and Clinical Health Sciences Vol.8 Issue 3, pp.660-667

Belge Tipi:

Makale

Yayın Tarihi:

9/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001326493

pISSN:

2564-7288

Anahtar kelimeler:

Özet:

 Purpose: Sodium-glucose cotransporter-2 SGLT-2 inhibitors are primarily preferred in patients with type 2 diabetes. The purpose of this paper was to elucidate the effects of SGLT-2 inhibitor use on patients voiding habits, sleep, and quality of life. Methods: Our study involved patients with type 2 diabetes who had an SGLT2 inhibitor added to their current treatment. The frequency of day-night urination, lower urinary tract symptoms, sleep and quality of life were assessed both prior to initiation of the treatment and during subsequent 1st and 3rd months. Results: The study included 38 women and 34 men. At the third month after SGLT-2 inhibitor had been added, there was a significant decrease in HbA1c, triglyceride and microalbumin levels p0.05. There was no increase in voiding frequency daynight and there was no difference in the evaluation of lower urinary tract symptoms, but voiding volumes increased in uroflowmetry. When the short form-36 SF-36 scale was examined, there was a significant improvement in physical function, one of the sub-parameters p  0.01. The factor affecting this most, was the improvement in HbA1c. Conclusion: This paper suggests that SGLT-2 inhibitors dont increase voiding frequency and dont cause an increase in lower urinary tract symptoms.

 Purpose: Sodium-glucose cotransporter-2 SGLT-2 inhibitors are primarily preferred in patients with type 2 diabetes. The purpose of this paper was to elucidate the effects of SGLT-2 inhibitor use on patients voiding habits, sleep, and quality of life. Methods: Our study involved patients with type 2 diabetes who had an SGLT2 inhibitor added to their current treatment. The frequency of day-night urination, lower urinary tract symptoms, sleep and quality of life were assessed both prior to initiation of the treatment and during subsequent 1st and 3rd months. Results: The study included 38 women and 34 men. At the third month after SGLT-2 inhibitor had been added, there was a significant decrease in HbA1c, triglyceride and microalbumin levels p0.05. There was no increase in voiding frequency daynight and there was no difference in the evaluation of lower urinary tract symptoms, but voiding volumes increased in uroflowmetry. When the short form-36 SF-36 scale was examined, there was a significant improvement in physical function, one of the sub-parameters p  0.01. The factor affecting this most, was the improvement in HbA1c. Conclusion: This paper suggests that SGLT-2 inhibitors dont increase voiding frequency and dont cause an increase in lower urinary tract symptoms.

 Purpose: Sodium-glucose cotransporter-2 SGLT-2 inhibitors are primarily preferred in patients with type 2 diabetes. The purpose of this paper was to elucidate the effects of SGLT-2 inhibitor use on patients voiding habits, sleep, and quality of life. Methods: Our study involved patients with type 2 diabetes who had an SGLT2 inhibitor added to their current treatment. The frequency of day-night urination, lower urinary tract symptoms, sleep and quality of life were assessed both prior to initiation of the treatment and during subsequent 1st and 3rd months. Results: The study included 38 women and 34 men. At the third month after SGLT-2 inhibitor had been added, there was a significant decrease in HbA1c, triglyceride and microalbumin levels p0.05. There was no increase in voiding frequency daynight and there was no difference in the evaluation of lower urinary tract symptoms, but voiding volumes increased in uroflowmetry. When the short form-36 SF-36 scale was examined, there was a significant improvement in physical function, one of the sub-parameters p  0.01. The factor affecting this most, was the improvement in HbA1c. Conclusion: This paper suggests that SGLT-2 inhibitors dont increase voiding frequency and dont cause an increase in lower urinary tract symptoms.

 Purpose: Sodium-glucose cotransporter-2 SGLT-2 inhibitors are primarily preferred in patients with type 2 diabetes. The purpose of this paper was to elucidate the effects of SGLT-2 inhibitor use on patients voiding habits, sleep, and quality of life. Methods: Our study involved patients with type 2 diabetes who had an SGLT2 inhibitor added to their current treatment. The frequency of day-night urination, lower urinary tract symptoms, sleep and quality of life were assessed both prior to initiation of the treatment and during subsequent 1st and 3rd months. Results: The study included 38 women and 34 men. At the third month after SGLT-2 inhibitor had been added, there was a significant decrease in HbA1c, triglyceride and microalbumin levels p0.05. There was no increase in voiding frequency daynight and there was no difference in the evaluation of lower urinary tract symptoms, but voiding volumes increased in uroflowmetry. When the short form-36 SF-36 scale was examined, there was a significant improvement in physical function, one of the sub-parameters p  0.01. The factor affecting this most, was the improvement in HbA1c. Conclusion: This paper suggests that SGLT-2 inhibitors dont increase voiding frequency and dont cause an increase in lower urinary tract symptoms.

Makale detayları

Do sodium glucose co-transporter-2 (sglt-2) inhibitors affect lower urinary tract, sleep and quality of life in people with type 2 diabetes?

Yazarlar:

Gökçen Güngör Semiz | Mehmet Emin Arayıcı | Ozan Bozkurt | Serkan Yener | Tevfik Demir

Yayıncı:

Dokuz Eylul University

Ana Başlıklar:

Endocrinology

Dergi:

Journal of Basic and Clinical Health Sciences Vol.8 Issue 3, pp.660-667

Belge Tipi:

Makale

Yayın Tarihi:

9/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001326493

pISSN:

2564-7288

Sodium-glucose cotrasporter-2 inhibitor

lower urinary tract symptoms

nocturia

quality of life

type 2 diabetes.

Sayı

Makale detayları

Do sodium glucose co-transporter-2 (sglt-2) inhibitors affect lower urinary tract, sleep and quality of life in people with type 2 diabetes?

Yazarlar: Gökçen Güngör Semiz | Mehmet Emin Arayıcı | Ozan Bozkurt | Serkan Yener | Tevfik Demir

Yayıncı: Dokuz Eylul University

Ana Başlıklar: Endocrinology

Dergi: Journal of Basic and Clinical Health Sciences Vol.8 Issue 3, pp.660-667

Belge Tipi: Makale

Yayın Tarihi: 9/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001326493

pISSN: 2564-7288

Sodium-glucose cotrasporter-2 inhibitor

lower urinary tract symptoms

nocturia

quality of life

type 2 diabetes.

Sayı

Yazarlar:

Gökçen Güngör Semiz | Mehmet Emin Arayıcı | Ozan Bozkurt | Serkan Yener | Tevfik Demir

Yayıncı:

Dokuz Eylul University

Ana Başlıklar:

Endocrinology

Dergi:

Journal of Basic and Clinical Health Sciences Vol.8 Issue 3, pp.660-667

Belge Tipi:

Makale

Yayın Tarihi:

9/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001326493

pISSN:

2564-7288